natgillin/translations-raw huggingface dataset:
Souběžné podávání přípravku EVOTAZ s warfarinem může vyvolat závažné a/nebo život ohrožující krvácení vlivem zvýšených plazmatických koncentrací warfarinu a doporučuje se sledování hodnoty INR (International Normalized Ratio) (viz bod 4.5).
Co-administration of EVOTAZ with warfarin has the potential to produce serious and/or life- threatening bleeding due to increased warfarin plasma concentrations, and it is recommended that the INR (International Normalized Ratio) be monitored (see section 4.5).
Souběžné podávání přípravku EVOTAZ se simeprevirem se nedoporučuje.
Recommendations concerning co- administration
Souběžné podávání přípravku EVOTAZ u pacientů užívajících léčivé přípravky, které jsou substráty transportérů P-gp, BCRP, MATE1, OATP1B1 a OATP1B3, může vést ke zvýšeným plazmatickým koncentracím současně podávaných léčivých přípravků (viz bod 4.4).
Co-administration of EVOTAZ in patients receiving medicinal products that are substrates of the transporters P-gp, BCRP, MATE1, OATP1B1 and OATP1B3 may result in increased plasma concentrations of the co- administered medicinal products (see section 4.4).
Souběžné podávání s antiretrivirovými léčivými přípravky
Co-administration with antiretroviral medicinal products
Souběžné podávání s bepridilem je kontraindikováno (viz bod 4.3).
Co-administration with bepridil is contraindicated (see section 4.3).
Souběžné podávání s následujícími léčivými přípravky vzhledem k možnosti vzniku závažných a/nebo život ohrožujících nežádoucích účinků (viz bod 4.5):
Co-administration with the following medicinal products due to the potential for serious and/or life- threatening adverse reactions (see section 4.5):
Souběžné podávání s následujícími léčivými přípravky, které jsou silnými spouštěči izoformy CYP3A4 cytochromu P450, vzhledem k možné ztrátě terapeutického účinku (viz bod 4.5):
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics)
Souběžné podávání s přípravkem EVOTAZ a rivaroxabanem může vyvolat zvýšenou expozici rivaroxabanu a může vést ke zvýšenému krvácení.
Co-administration of EVOTAZ and rivaroxaban may result in increased exposure to rivaroxaban and may lead to increased bleeding.
Souběžné podávání s přípravkem EVOTAZ může vyvolat zvýšení koncentrací salmeterolu a zvýšit nežádoucí účinky spojené s užíváním salmeterolu.
Co-administration with EVOTAZ may result in increased concentrations of salmeterol and an increase in salmeterol- associated adverse events.
Souběžné podávání s přípravkem EVOTAZ může vést ke zvýšení koncentrace inhibitoru PDE5 a zvýšenému výskytu nežádoucích účinků spojených s užíváním inhibitorů PDE5.
Co-administration with EVOTAZ may result in increased concentrations of the PDE5 inhibitor and an increase in
Souběžné podávání s přípravkem EVOTAZ může vést ke zvýšeným koncentracím
Co-administration with EVOTAZ may result in increased concentrations of the PDE5
Souběžné podávání s přípravkem EVOTAZ může zvyšovat plamatické koncentrace léčivých přípravků, které se metabolizují prostřednictvím CYP2D6 (viz body 4.3 a 4.5).
Co- administration with EVOTAZ can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.5).
Souběžné podávání s přípravkem EVOTAZ může zvyšovat plazmatické koncentrace warfarinu.
Co-administration with EVOTAZ has the potential to increase warfarin plasma concentrations.
Souběžné podávání salmeterolu s přípravkem EVOTAZ se nedoporučuje (viz bod 4.4).
Co-administration of salmeterol with EVOTAZ is not recommended (see section 4.4).
Souběžné podávání se nedoporučuje (viz bod 4.4).
Co-administration is not recommended (see section 4.4).
Souběžné podávání sildenafilu užívaného k léčbě plicní arteriální hypertenze je kontraindikováno (viz bod 4.3).
Sildenafil, when used for the treatment of pulmonary arterial hypertension, is contraindicated (see section 4.3).
Souběžné podávání simvastatinu nebo lovastatinu a přípravku EVOTAZ je kontraindikováno kvůli zvýšenému riziku myopatie včetně rhabdomyolýzy (viz bod 4.3).
Co-administration of simvastatin or lovastatin with EVOTAZ is contraindicated due to an increased risk of myopathy including rhabdomyolysis (see section 4.3).
Souběžné podávání vorikonazolu a přípravku EVOTAZ se nedoporučuje, pokud zhodnocení přínosu a rizika neopravňuje k použití vorikonazolu (viz bod 4.5).
Co-administration of voriconazole and EVOTAZ is not recommended unless an assessment of the benefit/risk justifies the use of voriconazole (see section 4.5).
Souběžné používání přípravku EVOTAZ a flutikason-propionátu nebo jiných inhalačních či nazálních kortikosteroidů se nedoporučuje, pokud potenciální přínos léčby nepřeváží rizika účinků systémových kortikosteroidů (viz bod 4.4).
Concomitant use of EVOTAZ and fluticasone propionate or other inhaled or nasal corticosteroids is not recommended unless the potential benefit of treatment outweighs the risks of systemic corticosteroid effects (see section 4.4).
Souběžné užívání je kontraindikováno
Concomitant use contraindicated
Souběžné užívání přípravku EVOTAZ a flutikasonu nebo jiných glukokortikoidů, které se metabolizují prostřednictvím CYP3A4, se nedoporučuje, pokud potenciální přínos léčby nepřeváží riziko účinků systémových kortikosteroidů včetně Cushingova syndromu a suprese nadledvin (viz bod 4.5).
Concomitant use of EVOTAZ and fluticasone or other glucocorticoids that are metabolized by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).
Souběžné užívání se nedoporučuje
Concomitant use not recommended
Souběžné užívání třezalky tečkované a přípravku EVOTAZ může vést k výraznému snížení plazmatických hladin atazanaviru.
Concomitant use of St. John's wort with EVOTAZ may be expected to result in significant reduction in plasma levels of cobicistat and atazanavir.
souběžného podávání přípravku
further information regarding co
souběžně s didanosinem
administered with didanosine
Souhrn bezpečnostního profilu
Summary of the safety profile
Souhrn údajů o přípravku (mSPC) a příbalová informace
Summary of Product Characteristics (SmPC) and Package Leaflet
Souhrnné údaje
Pooled data
South San Francisco CA 94080-4990 САЩ
South San Francisco CA 94080-4990 USA
South San Francisco, CA 94080-4990
South San Francisco, CA 94080-4990 USA
South Wales Обединено кралство
South Wales United Kingdom
Současná léčba cyklosporinem (viz bod 4.5)
Concurrent treatment with ciclosporin (see section 4.5)
Současná léčba warfarinem nebo jinými perorálními antikoagulancii (viz body 4.5 a 4.8)
Concurrent treatment with warfarin or other oral anticoagulants (see sections 4.5 and 4.8)
Současné dostupné údaje jsou popsány v bodech 4.8, 5.1 a 5.2, ale nemůže být vydáno žádné doporučení týkající se dávkování.
Currently available data are described in sections 4.8, 5.1 and 5.2, but no recommendation on a posology can be made.
Současné podání přípravku Intuniv a kyseliny valproové může mít za následek zvýšení koncentrace kyseliny valproové.
Co-administration of Intuniv and valproic acid can result in increased concentrations of valproic acid.
Současné podávání alli a warfarinu nebo jiných perorálních antikoagulancií je kontraindikováno (viz bod 4.3).
Concurrent use of alli and warfarin or other oral anticoagulants is contraindicated (see section 4.3).
Současné podávání s psychostimulancii
Co-administration with Psychostimulants
Současné užívání alli a cyklosporinu je kontraindikováno (viz bod 4.3).
Concurrent use of alli and ciclosporin is contraindicated (see section 4.3).
současně podávat EVOTAZ
co-administer EVOTAZ with an H2
Součástí každého balení je přenosné pouzdro z polystyrenové pryže/polyurethanu (shuttle), do kterého je možno uložit 3 tablety.
A polystyrene resin/polyurethane carry case (shuttle) which can hold 3 tablets is included in each pack.
Součástí každého balení je přenosné pouzdro z polystyrenové pryže/polyurethanu (shuttle), do kterého je možno uložit 3 tobolky.
A polystyrene resin / polyurethane carry case (shuttle) which can hold 3 capsules is included in each pack.
Sovaldi + рибавирин + пегинтерферон алфа
Sovaldi + ribavirin + peginterferon alfa
Sovaldi 400 mg филмирани таблетки
Sovaldi 400 mg film-coated tablets
Sovaldi 400 mg филмирани таблетки софосбувир
Sovaldi 400 mg film-coated tablets sofosbuvir
Sovaldi [само върху вторичната опаковка]
Sovaldi [Outer packaging only]
Sovaldi е антивирусно лекарство, което съдържа активното вещество софосбувир (sofosbuvir).
Sovaldi is an antiviral medicine that contains the active substance sofosbuvir.
Sovaldi е противопоказан с жълт кантарион - мощен индуктор на P-gp в червата (вж. точка 4.3).
Sovaldi is contraindicated with St. John’s wort, a potent intestinal P-gp inducer (see section 4.3).
Sovaldi е противопоказан с рифампицин - мощен индуктор на P-gp в червата (вж. точка 4.3).
Sovaldi is contraindicated with rifampicin, a potent intestinal P-gp inducer (see section 4.3).
Sovaldi не се препоръчва за приложение като монотерапия и трябва да се предписва в комбинация с други лекарствени продукти за лечение на хепатит С инфекция.
Sovaldi is not recommended for administration as monotherapy and should be prescribed in combination with other medicinal products for the treatment of hepatitis C infection.
Sovaldi не увеличава честотата или тежестта на тези нежелани реакции.
Sovaldi did not increase the frequency or severity of these side effects.
Sovaldi основно е проучен в комбинация с рибавирин, със или без пегинтерферон алфа.
Sovaldi has mainly been studied in combination with ribavirin, with or without peginterferon alfa.
Sovaldi позволява елиминиране на инфекцията, без да е необходимо пациентът да приема пегинтерферон алфа или с прилагане на това лекарство само за кратки терапевтични курсове (което може да причини сериозни нежелани лекарствени реакции и не се понася добре от много пациенти).
Sovaldi allows the infection to be cleared without the patient having to take peginterferon alfa or with only short courses of this medicine (which may cause serious side effects and is not well tolerated by many patients).
Sovaldi се използва в комбинация с други лекарства.
Sovaldi is used in combination with other medicines.
Sovaldi се използва често заедно с рибавирин.
Sovaldi is commonly used together with ribavirin.
Sovaldi се отпуска по лекарско предписание и лечението трябва да бъде започнато и да се проследява от лекар с опит в лечението на пациенти с хроничен хепатит C.
Sovaldi can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with chronic hepatitis C.
Sovaldi се предлага под формата на таблетки от 400 mg.
Sovaldi is available as 400 mg tablets.
Sovaldi трябва да се прилага в комбинация с други лекарства, използвани за лечение на хроничен хепатит С, като рибавирин или пегинтерферон алфа и рибавирин.
Sovaldi must be used in combination with other medicines used to treat chronic hepatitis C, such as ribavirin or peginterferon alfa and ribavirin.
Sovicille (SI), Италия.
Sovicille (SI), Italy.
Soya-bean oil Macrogol 3350
Macrogol 3350
Sočasna uporaba drugih fluoropirimidinov z zdravilom Teysuno.
Co-administration of other fluoropyrimidines with Teysuno.
Sočasna uporaba drugih fluoropirimidinov, kot so kapecitabin, 5-FU, tegafur in flucitozin, lahko povzroči aditivne toksične učinke, poleg tega pa je kontraindicirana.
Co-administration of other fluoropyrimidines such as capecitabine, 5-FU, tegafur, or flucytosine can lead to additive toxicities, and is contraindicated.
Sočasna uporaba imunomodulatorjev ni imela pomembnega vpliva na razpoložljivost ustekinumaba.
Concomitant use of immunomodulators did not have a significant impact on ustekinumab disposition.
Sočasna uporaba omeprazola (20 mg dvakrat na dan) se je začela najmanj 2 dni pred injiciranjem PhotoBarra.
Co-administration of omeprazole (20 mg BID) began at least 2 days before PhotoBarr injection.
Sočasna uporaba z zdravilom Klopidogrel Teva Pharma B.V. ni priporočena. zaviralce glikoproteina IIb/IIIb (zdravila, ki se uporabljajo za preprečevanje strjevanja krvi).
Their use with Clopidogrel Teva Pharma B.V. is not recommended.
Sočasni uporabi antipsihotičnih zdravil in pramipeksola se je treba izogibati (glejte poglavje 4.4), npr. kadar je pričakovan antagonistični učinek.
Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.4), e.g. if antagonistic effects can be expected.
Sočasni uporabi antipsihotičnih zdravil in pramipeksola se je treba izogibati (glejte poglavje 4.5).
Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.5).
Sočasno cepljenje proti rumeni mrzlici (glejte poglavje 4.5).
Concomitant yellow fever vaccine (see section 4.5).
Sočasno dajanje klopidogrela s peroralnimi antikoagulansi ni priporočljivo, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
Sočasno dajanje nefrotoksičnih zdravil (denimo, aminoglikozidov, diuretikov zanke, spojin platine, ciklosporina) lahko potencialno povzroči zakasnjeni očistek pemetrekseda.
Concomitant administration of nephrotoxic drugs (e.g., aminoglycoside, loop diuretics, platinum compounds, ciclosporin) could potentially result in delayed clearance of pemetrexed.
Sočasno dajanje snovi, ki se tudi izločajo s tubulno sekrecijo (denimo, probenecid, penicilin), lahko potencialno povzroči zakasnjeni očistek pemetrekseda.
Concomitant administration of substances that are also tubularly secreted (e.g., probenecid, penicillin) could potentially result in delayed clearance of pemetrexed.
Sočasno imunosupresivno zdravljenje
Concomitant immunosuppressive therapy
Sočasno jemanje s hrano stopnje absorpcije pramipeksola ne zmanjša, vendar pa se zmanjša hitrost absorpcije.
Concomitant administration with food did not reduce the extent of pramipexole absorption, but the rate of absorption was reduced.
Sočasno uporabo z zdravilom Teysuno je treba preprečiti.
Therefore, concurrent administration with Teysuno should be avoided.
SP (Brinny) Company Innishannon - County Cork Ирландия
SP (Brinny) Company Innishannon - County Cork Ireland
SP Europe, 73, rue de Stalle, B-1180 Bruxelles, Белгия
SP Europe, 73, rue de Stalle, B-1180 Bruxelles, Belgium
SP= серопротекция SC= сероконверсия
SP= seroprotection SC= seroconversion
Spaces Zuidas II, Barbara Strozzilaan 101, 1083HN Amsterdam, Нидерландия
Spaces Zuidas II, Barbara Strozzilaan 101, 1083HN Amsterdam, The Netherlands
Spara denna information, du kan behöva läsa den igen.
You may need to read it again.
Spara flaskan med oral lösning så att du enkelt kan beskriva vad du har tagit.
Keep the oral solution bottle with you so that you can easily describe what you have taken.
Spara kartongen så att du enkelt kan beskriva vad du har tagit.
Keep the carton with you so that you can easily describe what you have taken.
SPARCC (Консорциум на Канада за изследване на спондилоартрита)
SPARCC (Spondyloarthritis Research Consortium of Canada)
SPARCC MRI Spineг,й
SPARCC MRI Spined,j
SPARCC MRI Гръбнакй
SPARCC MRI Spined,j
SPARCCз MRI (Сакроилиачни стави)и
SPARCCh MRI Sacroiliac Jointsd,i
SPARCCз MRI Sacroiliac Jointsг,и
SPARCCh MRI Sacroiliac Jointsd,i
SPARKLE S.r.l.
SPARKLE S.r.l
Specifične študije še niso bile opravljene pri bolnikih, ki so pred kratkim prejeli živa virusna ali živa bakterijska cepiva.
Specific studies have not been conducted in patients who had recently received live viral or live bacterial vaccines.
Specifični antidot ni znan.
pecific antidote is known.
Spectrila 10 000 U прах за концентрат за инфузионен разтвор Аспарагиназа
Spectrila 10,000 U powder for concentrate for solution for infusion Asparaginase
Spectrila повлиява в умерена степен способността за шофиране и работа с машини, по- специално чрез своите потенциални ефекти върху нервната система и стомашно-чревния тракт (вж. точка 4.8).
Spectrila has moderate influence on the ability to drive and use machines, especially through its potential effects on the nervous and gastrointestinal systems (see section 4.8).
Spectrila се използва за лечение на възрастни и деца с остра лимфобластна левкемия (ОЛЛ) , която е форма на рак на кръвта.
Spectrila is used to treat adults and children with acute lymphoblastic leukaemia (ALL) which is a form of blood cancer.
Spectrila се предлага като прах за концентрат за инфузионен разтвор.
Spectrila is provided as a powder for concentrate for solution for infusion.
Spectrila се прилага на всеки 3 дни чрез инфузия (вливане) във вена, като дозата зависи от възрастта на пациента и телесната му повърхност.
Spectrila is given every 3 days by infusion (drip) into a vein, with the dose depending on the patient’s age and body surface area.
Spedra 100 mg таблетки
Spedra 100 mg tablets
Spedra 100 mg таблетки аванафил
Spedra 100 mg tablets avanafil
Spedra 200 mg таблетки
Spedra 200 mg tablets
Spedra 200 mg таблетки аванафил
Spedra 200 mg tablets avanafil
Spedra 50 mg таблетки
Spedra 50 mg tablets
Spedra 50 mg таблетки аванафил
Spedra 50 mg tablets avanafil
Spedra може да се приема със или без храна.
Spedra may be taken with or without food.
Spedra не е показан за употреба при жени.
Spedra is not indicated for use in women.
Spedra не лекува Вашето състояние.
Spedra does not cure your condition.
Speke Operations Fleming Road Liverpool
Speke Operations, Fleming Road, Liverpool,
sPGA “чисто” или “минимално”, n (%)
sPGA “clear” or “minimal”, n (%)
sPGA „0“ (изчистен)
sPGA of “0” (clear)
SPID за лекуваните с PecFent епизоди също е значително различна в сравнение с плацебо на 10, 15, 45 и 60 минути след приложение.
The SPID for PecFent-treated episodes was also significantly different to placebo at 10 15, 45 and 60 minutes after administration.
spinosad 270 mg/milbemycin oxime 4,5 mg spinosad 425 mg/milbemycin oxime 7,1 mg spinosad 665 mg/milbemycin oxime 11,1 mg spinosad 1040 mg/milbemycin oxime 17,4 mg spinosad 1620 mg/milbemycin oxime 27 mg
spinosad 270 mg/milbemycin oxime 4.5 mg spinosad 425 mg/milbemycin oxime 7.1 mg spinosad 665 mg/milbemycin oxime 11.1 mg spinosad 1040 mg/milbemycin oxime 17.4 mg spinosad 1620 mg/milbemycin oxime 27 mg
Spironolactone Ceva
EU/2/07/074/002
Spironolactone Ceva
EU/2/07/074/003
Spironolactone Ceva
EU/2/07/074/004
Spironolactone Ceva
EU/2/07/074/005
Spironolactone Ceva
EU/2/07/074/006
Spironolactone Ceva
EU/2/07/074/007
Spironolactone Ceva
EU/2/07/074/008
Spironolactone Ceva 10 mg tablets for dogs Spironolactone Ceva 10 мг таблетки за кучета Spironolactone Ceva 40 mg tablets for dogs Spironolactone Ceva 40 мг таблетки за кучета Spironolactone Ceva 80 mg tablets for dogs Spironolactone Ceva 80 мг таблетки за кучета
Spironolactone Ceva 10 mg tablets for dogs Spironolactone Ceva 40 mg tablets for dogs Spironolactone Ceva 80 mg tablets for dogs
Spironolactone Ceva 10 mg tablets for dogs Spironolactone Ceva 10 мг таблетки за кучета Spironolactone Ceva 40 mg tablets for dogs Spironolactone Ceva 40 мг таблетки за кучета Spironolactone Ceva 80 mg tablets for dogs Spironolactone Ceva 80 мг таблетки за кучета
Spironolactone Ceva 10 mg tablets for dogs Spironolactone Ceva 40 mg tablets for dogs Spironolactone Ceva 80 mg tablets for dogs Spironolactone.
Spironolactone Ceva 10 мг
Spironolactone Ceva 10 mg
Spironolactone Ceva 10 мг съдържа 10 мг spironolactоne Spironolactone Ceva 40 мг съдържа 40 мг spironolactоne Spironolactone Ceva 80 мг съдържа 80 мг spironolactоne
Spironolactone Ceva 10 mg contains 10 mg spironolactone Spironolactone Ceva 40 mg contains 40 mg spironolactone Spironolactone Ceva 80 mg contains 80 mg spironolactone
Spironolactone Ceva 10 мг таблетки за кучета Spironolactone Ceva 40 мг таблетки за кучета Spironolactone Ceva 80 мг таблетки за кучета
Spironolactone Ceva 10 mg tablets for dogs Spironolactone Ceva 40 mg tablets for dogs Spironolactone Ceva 80 mg tablets for dogs
Spironolactone може да причини както индукция, така и инхибиране на цитохром Р450 ензимите и така може да повлияе метаболизма на други продукти, използващи тези метаболитни пътища.
Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could affect the metabolism of other substances utilizing these metabolic pathways.
Spironolactone се метаболизира бързо и цялостно в черния дроб до неговите активни метоболити, 7α-тиометил-спиронолактон и канренон, които са първичните метаболити при кучето.
Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7α- thiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog.
Splošni varnostni ukrepi
General precautions
Splošno
General
Splošno: splošno poslabšanje stanja, povečanje telesne mase, pordelost in otekanje na mestu injiciranja, bolečine pri raku in krvavitev, odpoved več organov
General: general condition worsening, weight increase, redness and swelling at the injection site, cancer pain and bleeding, multiple organ failure
Spodaj navedeni podatki o varnosti zdravila temeljijo na stopnjah izpostavljenosti ustekinumabu v 12 študijah faze II in III pri 5.884 odraslih bolnikih (4.135 bolnikih s psoriazo in/ali psoriatičnim artritisom in 1.749 bolniki s Crohnovo boleznijo).
The safety data described below reflect exposure in adults to ustekinumab in 12 phase 2 and phase 3 studies in 5,884 patients (4,135 with psoriasis and/or psoriatic arthritis and 1,749 with Crohn’s disease).
Spodaj navedeni podatki o varnosti zdravila temeljijo na stopnjah izpostavljenosti ustekinumabu v 12 študijah faze II in III pri 5.884 odraslih bolnikih (4.135 bolnikih s psoriazo in/ali psoriatičnim artritisom in 1.749 bolnikih s Crohnovo boleznijo).
The safety data described below reflect exposure in adults to ustekinumab in 12 phase 2 and phase 3 studies in 5,884 patients (4,135 with psoriasis and/or psoriatic arthritis and 1,749 with Crohn’s disease).
Spodnja meja višja od –15 % dokazuje ne- manjvrednost palonosetrona proti primerjanemu zdravilu c Hi kvadrat test.
A lower bound greater than –15 % demonstrates non-inferiority between palonosetron and comparator. c Chi-square test.
Spodnja meja višja od –15 % dokazuje ne- manjvrednost zdravila Palonosetron Hospira proti primerjanemu zdravilu. c Hi kvadrat test.
A lower bound greater than –15 % demonstrates non-inferiority between palonosetron and comparator. c Chi-square test.
Spojené kráľovstvo (Veľká Británia) Tel: + 44 (0) 1896 664000
Spojené kráľovstvo (Veľká Británia) Tel: + 44 (0)1896 664000
spojených s rifabutinem včetně
due to an expected increase in
Spol
Gender
Spol bolnika ne vpliva na farmakokinetiko palonosetrona.
Gender does not affect the pharmacokinetics of palonosetron.
Spol ni vplival na CL/F ustekinumaba.
The CL/F of ustekinumab was not impacted by gender.
Spol, n (%) Moški Ženske
Gender, n (%) Male Female
Spot-on Разтвор
Spot-on solution
Spot-on приложение
Spot-on use
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
Justification for not including Braille accepted
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
Justification for not including Braille accepted.
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
Justification for not including in Braille accepted.
Sprememba od začetne vrednosti
Change from baseline Mean (SD)d
Sprememba odmerka cisplatina na začetku cikla zdravljenja
Cisplatin dose modification at the start of the cycle of treatment
Sprememba odmerka zdravila Teysuno
Teysuno dose modification
Sprememba odmerka zdravila Teysuno na začetku cikla zdravljenja
Teysuno dose modification at the start of the cycle of treatment
Spremembe odmerkov za posebne populacije
Dose modifications for special populations
Spremembe odmerkov zaradi hematološke toksičnosti
Dose modifications for haematologic toxicities
Spremembe odmerkov zaradi ledvične toksičnosti
Dose modifications for renal toxicities
Spremembe odmerkov zaradi toksičnosti morajo potekati skladno s Preglednicami 1, 3, 4 in 5.
Dose modifications for toxicity should be made according to Tables 1, 3, 4, and 5.